These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 31440832)

  • 1. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
    Proesmans VLJ; Drent M; Elfferich MDP; Wijnen PAHM; Jessurun NT; Bast A
    Lung; 2019 Oct; 197(5):551-558. PubMed ID: 31440832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
    Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
    Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
    Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
    BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
    Kou M; Jiao Y; Li Z; Wei B; Li Y; Cai Y; Wei W
    Eur J Clin Pharmacol; 2024 Oct; 80(10):1445-1460. PubMed ID: 38963453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study.
    Moor CC; Mostard RLM; Grutters JC; Bresser P; Aerts JGJV; Dirksen CD; Kimman ML; Wijsenbeek MS
    Respir Res; 2020 Jul; 21(1):196. PubMed ID: 32703201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
    Belhassen M; Dalon F; Nolin M; Van Ganse E
    Respir Res; 2021 May; 22(1):135. PubMed ID: 33947414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
    Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
    Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
    Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
    Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
    Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
    Flaherty KR; Fell CD; Huggins JT; Nunes H; Sussman R; Valenzuela C; Petzinger U; Stauffer JL; Gilberg F; Bengus M; Wijsenbeek M
    Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study.
    Zhao R; Xie B; Wang X; Zhang X; Ren Y; Wang C; Dai H
    Pulm Pharmacol Ther; 2024 Mar; 84():102287. PubMed ID: 38242314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
    Corral M; DeYoung K; Kong AM
    BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Doubkova M; Kriegova E; Littnerova S; Schneiderova P; Sterclova M; Bartos V; Plackova M; Zurkova M; Bittenglova R; Lostaková V; Siskova L; Lisa P; Suldova H; Doubek M; Psikalova J; Snizek T; Musilova P; Vasakova M
    Ther Adv Respir Dis; 2021; 15():17534666211042529. PubMed ID: 34515605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
    Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
    Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
    Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
    Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
    Vancheri C; Kreuter M; Richeldi L; Ryerson CJ; Valeyre D; Grutters JC; Wiebe S; Stansen W; Quaresma M; Stowasser S; Wuyts WA;
    Am J Respir Crit Care Med; 2018 Feb; 197(3):356-363. PubMed ID: 28889759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis.
    Perelas A; Glennie J; van Kerkhove K; Li M; Scheraga RG; Olman MA; Culver DA
    Pulm Pharmacol Ther; 2019 Dec; 59():101839. PubMed ID: 31518649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan.
    Hisata S; Bando M; Homma S; Kataoka K; Ogura T; Izumi S; Sakamoto S; Watanabe K; Saito Y; Shimizu Y; Kato M; Nishioka Y; Hara H; Waseda Y; Tanino Y; Yatera K; Hashimoto S; Mukae H; Inase N;
    Respir Investig; 2021 Nov; 59(6):819-826. PubMed ID: 33994347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.